Predictions
Paul Hartmann AG
Start price
Target price
Perf. (%)
€353.00
30.06.21
30.06.21
€400.00
30.06.22
30.06.22
3.40%
10.07.21
10.07.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
Ocuphire Pharma Inc.
Start price
Target price
Perf. (%)
€5.00
30.06.21
30.06.21
€8.00
30.06.22
30.06.22
-22.40%
09.07.21
09.07.21
Could be worthwhile Investment >10% per year
Good culture
Little innovation
Abivax S.A.
Start price
Target price
Perf. (%)
€30.50
28.06.21
28.06.21
€25.00
28.06.22
28.06.22
-16.39%
01.12.21
01.12.21
Future proof or reliable business model
Probably not worthwhile Investment
overvalued
Very low/no dividend yield expected
Syros Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€46.00
26.06.21
26.06.21
-
26.06.22
26.06.22
-81.82%
27.06.22
27.06.22
Could be very worthwhile Investment >20% year
Osmotica Pharmaceuticals PLC
Start price
Target price
Perf. (%)
€3.04
26.06.21
26.06.21
€1.00
26.06.22
26.06.22
-18.42%
10.07.21
10.07.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€16.08
24.06.21
24.06.21
€4.80
24.06.22
24.06.22
-60.12%
20.12.21
20.12.21
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Chemocentryx Inc.
Start price
Target price
Perf. (%)
€11.37
17.06.21
17.06.21
€18.00
09.03.22
09.03.22
95.60%
10.03.22
10.03.22
Could be very worthwhile Investment >20% year
Chemocentryx Inc.
Start price
Target price
Perf. (%)
€53.25
17.06.21
17.06.21
-
09.03.22
09.03.22
-
17.06.21
17.06.21
Could be very worthwhile Investment >20% year
Valneva SE
Start price
Target price
Perf. (%)
€10.89
17.06.21
17.06.21
€8.00
17.06.22
17.06.22
3.21%
20.07.21
20.07.21
Could be worthwhile Investment >10% per year
Very valuable balance sheet
Avid Bioservices Inc
Start price
Target price
Perf. (%)
€20.60
17.06.21
17.06.21
€17.00
17.06.22
17.06.22
38.84%
26.11.21
26.11.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€73.80
17.06.21
17.06.21
€50.00
17.06.22
17.06.22
-66.50%
17.08.21
17.08.21
Could be worthwhile Investment >10% per year
ShockWave Medical Inc
Start price
Target price
Perf. (%)
€159.00
16.06.21
16.06.21
€225.00
16.06.22
16.06.22
-5.66%
16.06.22
16.06.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Cocrystal Pharma Inc.
Start price
Target price
Perf. (%)
€13.20
14.06.21
14.06.21
€24.00
14.06.22
14.06.22
0.00%
26.06.21
26.06.21
Could be worthwhile Investment >10% per year
Good culture
Little innovation
Avid Bioservices Inc
Start price
Target price
Perf. (%)
€19.30
14.06.21
14.06.21
€22.00
14.06.22
14.06.22
6.74%
17.06.21
17.06.21
Could be worthwhile Investment >10% per year
CareCloud Inc.
Start price
Target price
Perf. (%)
€7.30
12.06.21
12.06.21
€8.50
12.06.22
12.06.22
-6.16%
10.07.21
10.07.21
Growths slower than the competition
Below average Marketposition
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Aptose Biosciences
Start price
Target price
Perf. (%)
€3.22
11.06.21
11.06.21
€4.00
11.06.22
11.06.22
-69.57%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€18.77
11.06.21
11.06.21
€23.20
11.06.22
11.06.22
-14.32%
24.06.21
24.06.21
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
M1 Kliniken AG
Start price
Target price
Perf. (%)
€10.35
31.05.21
31.05.21
-
31.05.24
31.05.24
40.10%
11.03.24
11.03.24
Could be worthwhile Investment >10% per year
Haemato AG
Start price
Target price
Perf. (%)
€29.20
31.05.21
31.05.21
-
31.05.24
31.05.24
-36.99%
11.03.24
11.03.24
Could be worthwhile Investment >10% per year
Sangamo Therapeutics Inc.
Start price
Target price
Perf. (%)
€8.74
31.05.21
31.05.21
€15.00
31.05.22
31.05.22
-60.61%
01.06.22
01.06.22
Fair valuation
Strong uniques
Leading role in innovation
Bad rating
Corvus Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€2.18
31.05.21
31.05.21
€4.00
31.05.22
31.05.22
4.59%
14.06.21
14.06.21
Could be worthwhile Investment >10% per year